Event
Prescription Digital Therapeutics: Measuring and Incentivizing Clinical Impact
Materials
Duke-Margolis_Prescription Digital Therapeutics_Convening_Agenda.pdf (160.43 KB)Duke-Margolis_Prescription Digital Therapeutics_Convening_Summary.pdf (204.54 KB)
On December 5th 2024, the Duke-Margolis Institute for Health Policy convened a group of expert stakeholders to discuss timely policy issues around the development and use of prescription digital therapeutics (PDTs). This group included PDT and pharmaceutical manufacturers, payers, PDT researchers, and legal, regulatory, and policy experts. This convening focused on challenges and solutions to robust evidence generation for PDTs, and potential reimbursement structures to support increased development and use of high-value products.
Our issue brief, "Building Value into Reimbursement for Prescription Digital Therapeutics," was released alongside this event and helped to inform the discussion that took place.
Convening Planning Team
Christina Silcox, PhD
Research Director, Digital Health
Adjunct Assistant Professor
Senior Team Member
Margolis Core Faculty
Sabine Sussman, MPH
Senior Policy Analyst
